Barinthus Biotherapeutics plc Cash Flow Quality Index
Barinthus Biotherapeutics plc cash flow quality index. Barinthus Biotherapeutics plc (BRNS) has a Cash Flow Quality Index of 1.45x as of September 2022. Operating cash flow of $11.88 Million exceeds net income of $8.22 Million, indicating high earnings quality where cash backs reported profits. See BRNS free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Cash Flow Quality Index of Barinthus Biotherapeutics plc (2022–2022)
Cash flow quality index of Barinthus Biotherapeutics plc from 2022 to 2022. Historical Cash Flow Quality Index for Barinthus Biotherapeutics plc across 1 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore BRNS debt coverage from operations to assess how comfortably operating cash covers total debt obligations.
Barinthus Biotherapeutics plc Cash Flow Quality Index by Year (2022–2022)
Barinthus Biotherapeutics plc cash flow quality index by year from 2022 to 2022. Year-by-year earnings quality comparison for Barinthus Biotherapeutics plc. For the full cash flow conversion analysis, see Barinthus Biotherapeutics plc operating cash flow efficiency.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2022 | -2.71x | $-14.43 Million | $5.32 Million | — |